BioCardia's Q2 Loss Widens Amid Zero Revenue, Going Concern Warning

TL;DR

**BioCardia is burning cash with no revenue, and without a major capital infusion by October, it's game over for this clinical-stage biotech.**

AI Summary

BioCardia, Inc. (BCDA) filed a 10-Q/A to include inadvertently omitted principal officer certifications, with no other changes to the original filing for the quarter ended June 30, 2025. The company reported a net loss of $2.049 million for the three months ended June 30, 2025, an increase from a net loss of $1.646 million in the prior-year period. For the six months ended June 30, 2025, the net loss was $4.761 million, compared to $3.913 million for the same period in 2024. Revenue from collaboration agreements decreased significantly, from $58,000 for the six months ended June 30, 2024, to $0 for the same period in 2025. Research and development expenses rose to $2.898 million for the six months ended June 30, 2025, up from $2.041 million in 2024, reflecting increased clinical trial activities. Selling, general and administrative expenses slightly decreased to $1.879 million from $1.941 million year-over-year. The company's cash and cash equivalents stood at $980,000 as of June 30, 2025, down from $2.371 million at December 31, 2024, and management believes this is insufficient to fund operations beyond October 2025, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

This 10-Q/A highlights BioCardia's precarious financial position, with a significant net loss of $4.761 million for the first half of 2025 and cash reserves of only $980,000, which management projects will last only until October 2025. The complete absence of collaboration agreement revenue, down from $58,000, signals a lack of immediate commercial traction or partnership income, while rising R&D costs of $2.898 million indicate continued investment in clinical trials. For investors, this raises serious questions about dilution risk from future capital raises and the long-term viability of the company's cell therapy platforms, especially in a competitive biotech landscape where funding is critical for clinical-stage companies.

Risk Assessment

Risk Level: high — The company explicitly states that its cash and cash equivalents of $980,000 as of June 30, 2025, are not sufficient to fund planned expenditures beyond October 2025, raising "substantial doubt about our ability to continue as a going concern." This, coupled with an accumulated deficit of $164.9 million and zero collaboration revenue for the six months ended June 30, 2025, indicates extreme financial distress.

Analyst Insight

Investors should avoid BCDA given the explicit going concern warning and rapid cash burn. Current shareholders should consider exiting their positions, as significant dilution or even cessation of operations is a near-term possibility if additional capital is not secured by October 2025.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$2.089M

total Debt

$3.975M

net Income

-$4.761M

eps

-$0.98

gross Margin

N/A

cash Position

$980,000

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $980K — Cash and Cash Equivalents (As of June 30, 2025, down from $2.371M at Dec 31, 2024, insufficient beyond Oct 2025.)
• $164.9M — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses.)
• $4.761M — Net Loss (6 months) (For the six months ended June 30, 2025, an increase from $3.913M in 2024.)
• $0 — Collaboration Agreement Revenue (For the six months ended June 30, 2025, down from $58K in 2024.)
• $2.898M — Research and Development Expenses (6 months) (For the six months ended June 30, 2025, up from $2.041M in 2024.)
• 5,801,224 — Shares Outstanding (As of August 8, 2025, indicating potential for further dilution.)
• $3.267M — Net Cash Used in Operating Activities (6 months) (For the six months ended June 30, 2025, reflecting ongoing cash burn.)
• $1.877M — Net Cash Provided by Financing Activities (6 months) (For the six months ended June 30, 2025, primarily from stock sales.)

Key Players & Entities

• BioCardia, Inc. (company) — registrant
• BCDA (company) — trading symbol on Nasdaq Capital Market
• Securities and Exchange Commission (regulator) — filing oversight
• Sarbanes-Oxley Act of 2002 (regulator) — mandates certifications
• Financial Accounting Standards Board (regulator) — issues accounting standards
• $980,000 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $2,371,000 (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $164.9 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $4.761 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $2.898 million (dollar_amount) — research and development expenses for the six months ended June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's cash and cash equivalents were $980,000 as of June 30, 2025, a decrease from $2,371,000 at December 31, 2024. Management estimates this is insufficient to fund operations beyond October 2025, raising substantial doubt about its ability to continue as a going concern.
• Increasing Net Losses [high — financial]: The net loss for the three months ended June 30, 2025, was $2.049 million, an increase from $1.646 million in the prior year. For the six months ended June 30, 2025, the net loss was $4.761 million, up from $3.913 million in the same period of 2024.
• Declining Revenue Streams [medium — financial]: Revenue from collaboration agreements has fallen to $0 for the six months ended June 30, 2025, from $58,000 in the comparable period of 2024, indicating a loss of income from key partnerships.
• Rising R&D Expenses [medium — operational]: Research and development expenses increased to $2.898 million for the six months ended June 30, 2025, from $2.041 million in the prior year, driven by increased clinical trial activities. While necessary for product development, this higher burn rate exacerbates cash concerns.
• Negative Stockholders' Equity [medium — financial]: As of June 30, 2025, the company has a total stockholders' deficit of $1.886 million, reflecting accumulated losses and a negative equity position.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like BioCardia often rely on external funding and strategic partnerships to advance their pipelines. The current environment favors companies with strong clinical data and clear paths to commercialization, while those facing financial distress and clinical setbacks are under intense scrutiny.

Regulatory Implications

As a biotechnology company, BioCardia is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, adverse findings, or failure to meet regulatory standards can significantly impact development timelines and market access. The company's financial instability could also affect its ability to meet ongoing compliance requirements.

What Investors Should Do

1. Monitor cash burn and future financing activities closely.
2. Evaluate the progress and results of ongoing clinical trials.
3. Assess the company's strategy for addressing the going concern issue.

Key Dates

• 2025-06-30: Quarter and Six-Month Period End — Reporting period for the financial results included in the 10-Q/A, highlighting increased net losses and reduced cash reserves.
• 2025-10-01: Estimated Cash Runway End — Management's projection that current cash will be insufficient to fund operations beyond this date, underscoring the immediate going concern risk.
• 2025-08-08: Shares Outstanding Reported — 5,801,224 shares outstanding as of this date, indicating potential for further dilution if equity financing is pursued.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates BioCardia has historically incurred more expenses than revenues, with a deficit of $164.882 million as of June 30, 2025.)

Going Concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. Auditors assess this based on financial health and operational viability. (Management's belief that the company may not be able to continue as a going concern due to insufficient cash raises significant doubt about its future operations.)

Collaboration Agreement Revenue

Revenue generated from partnerships or agreements with other companies, often involving joint development or licensing of technology. (This revenue stream has ceased for BioCardia, dropping to $0 for the six months ended June 30, 2025, from $58,000 in the prior year.)

Weighted-average shares used in computing net loss per share

The average number of outstanding shares during a reporting period, adjusted for the timing of share issuances or repurchases. Used to calculate earnings or loss per share. (The weighted-average shares increased significantly from 1,877,069 in the six months ended June 30, 2024, to 4,848,922 in the same period of 2025, reflecting share issuances.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, BioCardia has seen a significant deterioration in its financial performance. Collaboration revenue has dropped to zero, while net losses have widened for both the three-month and six-month periods ended June 30, 2025. Research and development expenses have increased substantially, contributing to a higher operating loss. The company's cash position has also declined sharply, leading to serious concerns about its ability to continue as a going concern.

Key Financial Figures

• $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Indicat
• $250,000 — mes exceeds federally insured limits of $250,000 per customer. On June 30, 2025, approxi

Filing Documents

• bcda20250630_10qa.htm (10-Q/A) — 776KB
• ex_877399.htm (EX-31.1) — 11KB
• ex_877400.htm (EX-31.2) — 10KB
• ex_877401.htm (EX-32.1) — 4KB
• ex_877402.htm (EX-32.2) — 4KB
• 0001437749-25-032197.txt ( ) — 4115KB
• bcda-20250630.xsd (EX-101.SCH) — 43KB
• bcda-20250630_def.xml (EX-101.DEF) — 270KB
• bcda-20250630_lab.xml (EX-101.LAB) — 237KB
• bcda-20250630_pre.xml (EX-101.PRE) — 299KB
• bcda-20250630_cal.xml (EX-101.CAL) — 26KB
• bcda20250630_10qa_htm.xml (XML) — 584KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 Part II. OTHER INFORMATION 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26 EXHIBIT INDEX 26

SIGNATURES

SIGNATURES 27 4 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws that involve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cell therapy systems, our clinical trials, and our business development initiatives, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or resources or other financial items, (iii) our need and ability to raise additional capital, (iv) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (v) our ability to develop and advance current product candidates and programs and execute on our corporate strategy and (vi) the assumptions underlying or relating to any statement described in points (i) – (v) above. These statements include those discussed in Item 2, Management ' s Discussion and Analysis of Financial Condition and Results of Operations, including " Critical Accounting Policies and Estimates, " " Results of Operations, " " Liquidity and Capital Resources, " and " Future Funding Requirements, " and elsewhere in this report. In this report, the words " may, " " could, " " would, " " might, " " will, " " should, " " plan, " " forecast, " " anticipate, " " believe, " " expect, " " intend, " " estimate, " " predict, " " potential, " " continue, " " future, " " moving toward " or the negative of these terms or other similar expressions also identify forward-looking statements. Our actual results could

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS BIOCARDIA, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 980 $ 2,371 Accounts receivable, net of allowance for doubtful accounts of $ 0 and $ 0 as of June 30, 2025 and December 31, 2024, respectively 10 — Prepaid expenses and other current assets 209 251 Total current assets 1,199 2,622 Property and equipment, net 17 33 Operating lease right-of-use asset, net 702 898 Other assets 171 171 Total assets $ 2,089 $ 3,724 Liabilities and Stockholders ' Equity (Deficit) Current liabilities: Accounts payable $ 1,233 $ 385 Accrued expenses and other current liabilities 1,997 1,551 Operating lease liability - current 412 385 Total current liabilities 3,642 2,321 Operating lease liability - noncurrent 333 566 Total liabilities 3,975 2,887 Commitments and contingencies (Notes 2, 5 and 11) Stockholders' equity (deficit): Preferred stock, $ 0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 50,000,000 shares authorized, 5,504,802 and 4,600,910 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 6 5 Additional paid-in capital 162,990 160,953 Accumulated deficit ( 164,882 ) ( 160,121 ) Total stockholders' equity (deficit) ( 1,886 ) 837 Total liabilities and stockholders' equity (deficit) $ 2,089 $ 3,724 See accompanying notes to the unaudited condensed consolidated financial statements. 6 BIOCARDIA, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (unaudited) Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024

View Full Filing

View this 10-Q/A filing on SEC EDGAR